The total adverse events and hypoglycemia were not different, log ratios=1.29, 95% CI 0.80-2.09, and log ratios=1.26, 95% CI 0.59-2.70, respectively.<h4>Discussion</h4>GLP-1 agonists are a promising and effective therapy for lowering weight, HbA1c, BMI z, and SBP in adolescents with obesity or youth with type 2 DM. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.